Legend Biotech
LEGN
206 hedge funds and large institutions have $5.22B invested in Legend Biotech in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 93 increasing their positions, 58 reducing their positions, and 27 closing their positions.
201% more call options, than puts
Call options by funds: $58.4M | Put options by funds: $19.4M
60% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 58
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
3% more funds holding
Funds holding: 200 → 206 (+6)
0.22% more ownership
Funds ownership: 26.05% → 26.27% (+0.22%)
10% less capital invested
Capital invested by funds: $5.78B → $5.22B (-$559M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$70.6M |
| 2 |
Morgan Stanley
New York
|
+$62.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$61M |
| 4 |
BlackRock
New York
|
+$40.9M |
| 5 |
Millennium Management
New York
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$197M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$69.3M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$35.9M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$31.8M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$28.6M |
LEGN Hedge Fund Activity: Q4 2023 in Review
206 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2023, worth a combined $5.22B — down 9.7% from $5.78B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new LEGN positions and 27 closed out — a net gain of 7 holders — while 93 added to existing stakes and 58 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $70.6M. The largest seller was Fidelity Investments, cutting an estimated $197M.
- 206 institutional investors held Legend Biotech (LEGN) as of Q4 2023, up from 200 in Q3 2023.
- Funds reported $5.22B of Legend Biotech stock for Q4 2023, down 9.7% quarter-over-quarter.
- 34 funds opened new Legend Biotech positions in Q4 2023 and 27 closed out, a net change of +7 holders.
- The largest Legend Biotech buyer in Q4 2023 was T. Rowe Price Associates, an estimated $70.6M added.
- The largest Legend Biotech seller in Q4 2023 was Fidelity Investments, an estimated $197M sold.
Based on aggregated 13F filings for Q4 2023.